Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors

Pharmacology and Therapeutics · Published 2026-07-29 · DOI 10.1016/j.pharmthera.2026.109090

Free full text

Authors (7)

Natalia Motzko Noto, Kaitlin Martin, Sebastian Fidelia, Mayur S. Parmar, Luigi X. Cubeddu, Narasimman Gurusamy, Robert C. Speth

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Noto, N., Martin, K., Fidelia, S., et al. (2026). Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors. Pharmacology and Therapeutics. https://doi.org/10.1016/j.pharmthera.2026.109090

Related articles

• Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review · Current Vascular Pharmacology · 2025 · Cites or is cited by this article
• Dapagliflozin attenuates lipotoxic tenocyte injury via PPARα activation and irisin-driven antioxidant pathways · Connective Tissue Research · 2025 · Cites or is cited by this article
• SGLT2 Inhibitors as Mitochondrial Therapies in Heart Failure: A Bioenergetic Revolution in Cardiometabolic Medicine · Current Cardiology Reviews · 2026 · Cites or is cited by this article
• The aftermath of alcohol misuse: Linking cellular damage, suboptimal micronutrient nutrition, and organ dysfunction · Pharmacology and Therapeutics · 2026 · Same journal
• A dive into the untapped potential of marine compounds in counteracting neurodegeneration · Pharmacology and Therapeutics · 2026 · Same journal
• Mathematical modeling of T cell exhaustion in the tumor microenvironment · Pharmacology and Therapeutics · 2026 · Same journal
• C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy · Pharmacology and Therapeutics · 2026 · Same journal
• Circular RNA serves as an upstream regulator of the miRNA//ABCC1 axis in human cancers · Pharmacology and Therapeutics · 2026 · Same journal
• Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk · Pharmacology and Therapeutics · 2026 · Same journal
• Therapeutic potential of targeting novel signaling pathways in regulating chronic inflammation in obstructive lung disorders · Pharmacology and Therapeutics · 2026 · Same journal